Results 41 to 50 of about 270,350 (354)

Aging on Chip: Harnessing the Potential of Microfluidic Technologies in Aging and Rejuvenation Research

open access: yesAdvanced Healthcare Materials, EarlyView.
This review highlights recent advances in microfluidic technologies for modeling human aging and age‐related diseases. It explores how organ‐on‐chip platforms improve physiological relevance, enable rejuvenation strategies, facilitate drug screening, detect senescent cells, and identify biomarkers.
Limor Zwi‐Dantsis   +5 more
wiley   +1 more source

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai   +10 more
doaj   +1 more source

Clinical course and outcomes in adults with co-occurring hypertrophic cardiomyopathy and hypertension: a scoping review protocol

open access: yesBMJ Open, 2023
Introduction Hypertension affects 40%–60% of adults with hypertrophic cardiomyopathy (HCM), the most common inherited cardiac condition. It can be a diagnostic confounder for HCM, contributing to delayed diagnosis.
Daniele Massera   +8 more
doaj   +1 more source

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy

open access: yesCirculation Genomic and Precision Medicine, 2020
Supplemental Digital Content is available in the text. Background: Pathogenic variants in MYBPC3, encoding cardiac MyBP-C (myosin binding protein C), are the most common cause of familial hypertrophic cardiomyopathy.
A. Helms   +22 more
semanticscholar   +1 more source

Development of Photo‐Biocatalytic Redox System for Asymmetric Synthesis of Optically Active Amines Using Blue Light and Transaminases. A Case Study Toward Mavacamten

open access: yesAdvanced Synthesis &Catalysis, EarlyView.
Abstract α‐Chiral amines are versatile building blocks for the asymmetric synthesis of optically pure high‐added‐value chemicals, including pharmaceuticals, agrochemicals, and natural products. Herein, we report a one‐pot, two‐step sequential deracemization of racemic sec‐alcohols to optically enriched primary amines throught a photo‐biocatalytic ...
Natalia Antos   +5 more
wiley   +1 more source

Non‐Invasive Diagnosis of Hypertrophic Cardiomyopathy by Breath

open access: yesAdvanced Sensor Research, EarlyView.
The use of sensor technologies for the diagnosis of hypertrophic cardiomyopathy (HCM) by identification of volatile organic compounds (VOCs) in breath samples. By combining gas chromatography‐mass spectrometry (GC‐MS) and electronic nose (eNose) platforms, specific VOC patterns associated with HCM are detected and analyzed.
Yael Hershkovitz‐Pollak   +5 more
wiley   +1 more source

[2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy].

open access: yesKardiologia polska, 2014
© 2015, Silicea-Poligraf. All Rights Reserved. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Perry M. Elliott   +19 more
semanticscholar   +1 more source

Neuraminidase 1 Exacerbated Glycolytic Dysregulation and Cardiotoxicity by Destabilizing SIRT1 through Interactions with NRF2 and HIF1α

open access: yesAdvanced Science, EarlyView.
NEU1, a key regulator of glycolysis, is markedly upregulated following DOX treatment. This upregulation is attributed to HIF1α’s transcriptional repression, requiring intricate interactions with NRF2. Increased NEU1 facilitates SIRT1 lysosomal degradation, contributing to aberrant glycolytic phenotype and cardiac damage.
Ting Gao   +13 more
wiley   +1 more source

Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: Development of advanced heart failure (HF) symptoms is the most common adverse pathway in hypertrophic cardiomyopathy (HCM) patients. Currently, there is a limited ability to identify HCM patients at risk of HF.Objectives: In this study, we ...
Ahmed S. Fahmy   +5 more
doaj   +1 more source

Reversal of Stress‐Induced PIEZO1 Elevation with Mechanically Adapted Epicardial Patch for Myocardial Infarction Treatment

open access: yesAdvanced Science, EarlyView.
This work identifies fine‐tuning the expression of PIEZO1 as a critical molecular mechanism underlying the treatment of myocardial infarction by mechanically adapted cardiac patches, which can support the clinical translation of cardiac patch devices.
Yuwen Lu   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy